Literature DB >> 23221568

Resistance to two heterologous neurotropic oncolytic viruses, Semliki Forest virus and vaccinia virus, in experimental glioma.

Markus J V Vähä-Koskela1, Fabrice Le Boeuf, Chantal Lemay, Naomi De Silva, Jean-Simon Diallo, Julie Cox, Michelle Becker, Youngmin Choi, Abhirami Ananth, Clara Sellers, Sophie Breton, Dominic Roy, Theresa Falls, Jan Brun, Akseli Hemminki, Ari Hinkkanen, John C Bell.   

Abstract

Attenuated Semliki Forest virus (SFV) may be suitable for targeting malignant glioma due to its natural neurotropism, but its replication in brain tumor cells may be restricted by innate antiviral defenses. We attempted to facilitate SFV replication in glioma cells by combining it with vaccinia virus, which is capable of antagonizing such defenses. Surprisingly, we found parenchymal mouse brain tumors to be refractory to both viruses. Also, vaccinia virus appears to be sensitive to SFV-induced antiviral interference.

Entities:  

Mesh：

Year:  2012        PMID： 23221568      PMCID： PMC3571476          DOI： 10.1128/JVI.01609-12

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  20 in total

1.  Interferon-β sensitivity of tumor cells correlates with poor response to VA7 virotherapy in mouse glioma models.

Authors:  Janne Ruotsalainen; Miika Martikainen; Minna Niittykoski; Tuulia Huhtala; Tytti Aaltonen; Jari Heikkilä; John Bell; Markus Vähä-Koskela; Ari Hinkkanen
Journal:  Mol Ther       Date:  2012-03-20       Impact factor: 11.454

2.  Quantifying viral propagation in vitro: toward a method for characterization of complex phenotypes.

Authors:  K A Duca; V Lam; I Keren; E E Endler; G J Letchworth; I S Novella; J Yin
Journal:  Biotechnol Prog       Date:  2001 Nov-Dec

3.  Differentially regulated interferon response determines the outcome of Newcastle disease virus infection in normal and tumor cell lines.

Authors:  Sateesh Krishnamurthy; Toru Takimoto; Ruth Ann Scroggs; Allen Portner
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

4.  Persistent virus infection inhibits type I interferon production by plasmacytoid dendritic cells to facilitate opportunistic infections.

Authors:  Elina I Zuniga; Li-Ying Liou; Lauren Mack; Marilyn Mendoza; Michael B A Oldstone
Journal:  Cell Host Microbe       Date:  2008-10-16       Impact factor: 21.023

5.  Efficacy of systemically administered oncolytic vaccinia virotherapy for malignant gliomas is enhanced by combination therapy with rapamycin or cyclophosphamide.

Authors:  Xue Qing Lun; Ji-Hyun Jang; Nan Tang; Helen Deng; Renee Head; John C Bell; David F Stojdl; Catherine L Nutt; Donna L Senger; Peter A Forsyth; J Andrea McCart
Journal:  Clin Cancer Res       Date:  2009-04-07       Impact factor: 12.531

6.  Differential effects of combined Ad5- delta 24RGD and radiation therapy in in vitro versus in vivo models of malignant glioma.

Authors:  Martine L M Lamfers; Sander Idema; Lisette Bosscher; Stan Heukelom; Sharif Moeniralm; Ida H van der Meulen-Muileman; Renée M Overmeer; Paul van der Valk; Victor W van Beusechem; Winald R Gerritsen; W Peter Vandertop; Clemens M F Dirven
Journal:  Clin Cancer Res       Date:  2007-12-15       Impact factor: 12.531

Review 7.  Engineering oncolytic viruses to exploit tumor specific defects in innate immune signaling pathways.

Authors:  Shruthi Naik; Stephen J Russell
Journal:  Expert Opin Biol Ther       Date:  2009-09       Impact factor: 4.388

8.  Comparative prime-boost vaccinations using Semliki Forest virus, adenovirus, and ALVAC vectors demonstrate differences in the generation of a protective central memory CTL response against the P815 tumor.

Authors:  Tanja I Näslund; Catherine Uyttenhove; Eva K L Nordström; Didier Colau; Guy Warnier; Mikael Jondal; Benoît J Van den Eynde; Peter Liljeström
Journal:  J Immunol       Date:  2007-06-01       Impact factor: 5.422

9.  Evaluation of cancer virotherapy with attenuated replicative Semliki forest virus in different rodent tumor models.

Authors:  Ann-Marie Määttä; Timo Liimatainen; Tiina Wahlfors; Thomas Wirth; Markus Vähä-Koskela; Linda Jansson; Piia Valonen; Katja Häkkinen; Outi Rautsi; Riikka Pellinen; Kimmo Mäkinen; Juhana Hakumäki; Ari Hinkkanen; Jarmo Wahlfors
Journal:  Int J Cancer       Date:  2007-08-15       Impact factor: 7.396

Review 10.  Oncolytic virotherapy: molecular targets in tumor-selective replication and carrier cell-mediated delivery of oncolytic viruses.

Authors:  Z Sheng Guo; Stephen H Thorne; David L Bartlett
Journal:  Biochim Biophys Acta       Date:  2008-02-15
View more
  11 in total

1.  Sindbis viral vectors transiently deliver tumor-associated antigens to lymph nodes and elicit diversified antitumor CD8+ T-cell immunity.

Authors:  Tomer Granot; Yoshihide Yamanashi; Daniel Meruelo
Journal:  Mol Ther       Date:  2013-09-12       Impact factor: 11.454

2.  Bacterial-mediated knockdown of tumor resistance to an oncolytic virus enhances therapy.

Authors:  Michelle Cronin; Fabrice Le Boeuf; Carola Murphy; Dominic G Roy; Theresa Falls; John C Bell; Mark Tangney
Journal:  Mol Ther       Date:  2014-02-26       Impact factor: 11.454

3.  Clonal variation in interferon response determines the outcome of oncolytic virotherapy in mouse CT26 colon carcinoma model.

Authors:  J J Ruotsalainen; M U Kaikkonen; M Niittykoski; M W Martikainen; C G Lemay; J Cox; N S De Silva; A Kus; T J Falls; J-S Diallo; F Le Boeuf; J C Bell; S Ylä-Herttuala; A E Hinkkanen; M J Vähä-Koskela
Journal:  Gene Ther       Date:  2014-09-18       Impact factor: 5.250

4.  MicroRNA-Attenuated Clone of Virulent Semliki Forest Virus Overcomes Antiviral Type I Interferon in Resistant Mouse CT-2A Glioma.

Authors:  Miika Martikainen; Minna Niittykoski; Mikael von und zu Fraunberg; Arto Immonen; Susanna Koponen; Maartje van Geenen; Markus Vähä-Koskela; Erkko Ylösmäki; Juha E Jääskeläinen; Kalle Saksela; Ari Hinkkanen
Journal:  J Virol       Date:  2015-08-12       Impact factor: 5.103

Review 5.  Oncolytic Alphaviruses in Cancer Immunotherapy.

Authors:  Kenneth Lundstrom
Journal:  Vaccines (Basel)       Date:  2017-04-12

Review 6.  Tumor Restrictions to Oncolytic Virus.

Authors:  Markus Vähä-Koskela; Ari Hinkkanen
Journal:  Biomedicines       Date:  2014-04-17

7.  Attenuated Semliki Forest virus for cancer treatment in dogs: safety assessment in two laboratory Beagles.

Authors:  Karoliina P M Autio; Janne J Ruotsalainen; Marjukka O Anttila; Minna Niittykoski; Matti Waris; Akseli Hemminki; Markus J V Vähä-Koskela; Ari E Hinkkanen
Journal:  BMC Vet Res       Date:  2015-07-28       Impact factor: 2.741

8.  Overcoming tumor resistance by heterologous adeno-poxvirus combination therapy.

Authors:  Markus Vähä-Koskela; Siri Tähtinen; Susanna Grönberg-Vähä-Koskela; Kristian Taipale; Dipongkor Saha; Maiju Merisalo-Soikkeli; Marko Ahonen; Noora Rouvinen-Lagerström; Mari Hirvinen; Ville Veckman; Sampsa Matikainen; Fang Zhao; Päivi Pakarinen; Jarmo Salo; Anna Kanerva; Vincenzo Cerullo; Akseli Hemminki
Journal:  Mol Ther Oncolytics       Date:  2015-01-07       Impact factor: 7.200

9.  Smac mimetics and innate immune stimuli synergize to promote tumor death.

Authors:  Shawn T Beug; Vera A Tang; Eric C LaCasse; Herman H Cheung; Caroline E Beauregard; Jan Brun; Jeffrey P Nuyens; Nathalie Earl; Martine St-Jean; Janelle Holbrook; Himika Dastidar; Douglas J Mahoney; Carolina Ilkow; Fabrice Le Boeuf; John C Bell; Robert G Korneluk
Journal:  Nat Biotechnol       Date:  2014-01-26       Impact factor: 54.908

Review 10.  The importance of imaging strategies for pre-clinical and clinical in vivo distribution of oncolytic viruses.

Authors:  Adrian Pelin; Jiahu Wang; John Bell; Fabrice Le Boeuf
Journal:  Oncolytic Virother       Date:  2018-03-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.